AM3 administration appears to reverse the non-responder status to hepatitis B vaccination in haemodialysis (HD) patients.

被引：0
|
作者：
Jarillo, MD
GarciaMartin, F
Sada, G
Calvo, CG
Prieto, A
Goni, M
Villarubia, VG
deMon, MA
机构：
[1] UNIV ALCALA DE HENARES, IMMUNOL IF CANTABRIA, HOSP GEN GUADALAJARA, SERV NEPHROL, MADRID, SPAIN
[2] UNIV ALCALA DE HENARES, IMMUNOL IF CANTABRIA, HOSP GEN GUADALAJARA, INTERNAL MED SERV, MADRID, SPAIN
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 1996年 / 7卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A2640 / A2640
页数：1
相关论文
共 42 条
  • [31] Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: Results of an open, controlled trial
    Jaboli, MF
    Fabbri, C
    Liva, S
    Azzaroli, F
    Nigro, G
    Giovanelli, S
    Ferrara, F
    Miracolo, A
    Marchetto, S
    Montagnani, M
    Colecchia, A
    Festi, D
    Reggiani, LB
    Roda, E
    Mazzella, G
    WORLD JOURNAL OF GASTROENTEROLOGY, 2003, 9 (07) : 1491 - 1495
  • [32] Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B:Results of an open,controlled trial
    M. Francesca Jaboli
    Carlo Fabbri
    Stefania Liva
    Francesco Azzaroli
    Giovanni Nigro
    Silvia Giovanelli
    Francesco Ferrara
    Anna Miracolo
    Sabrina Marchetto
    Marco Montagnani
    Antonio Colecchia
    Davide Festi
    Letizia Bacchi Reggiani
    Enrico Roda
    Giuseppe Mazzella
    World Journal of Gastroenterology, 2003, 9 (07) : 1491 - 1495
  • [33] A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B®, among vaccine naïve and vaccine non-responder dialysis patients
    E. Elhanan
    M. Boaz
    I. Schwartz
    D. Schwartz
    G. Chernin
    H. Soetendorp
    A Gal Oz
    A. Agbaria
    T. Weinstein
    Clinical and Experimental Nephrology, 2018, 22 : 151 - 158
  • [34] Hepatitis B vaccination status among patients with end-stage kidney disease on haemodialysis in Ethiopia: a multi-center cross-sectional study
    Annose, Rodas Temesgen
    Nur, Abdulsemed Mohammed
    Tsige, Abel Zemenfes
    Juhar, Leja Hamza
    Zegergsh, Arsema Goytom
    BMC NEPHROLOGY, 2024, 25 (01)
  • [35] Evolutionary dynamics of the E1-E2 viral populations during combination therapy in non-responder patients chronically infected with hepatitis C virus subtype 1b
    Saludes, Veronica
    Gonzalez-Candelas, Fernando
    Planas, Ramon
    Sola, Ricard
    Ausina, Vicente
    Martro, Elisa
    INFECTION GENETICS AND EVOLUTION, 2013, 13 : 1 - 10
  • [36] Efficacy of daily interferon-alpha-2b (IFN-A) in combination with Ribavirin in the treatment of non-responder patients with chronic hepatitis C (CHC): A randomised-controlled trial.
    Tassopoulos, NC
    Tsantoulas, D
    Raptopoulou, M
    Paraskevas, E
    Kanatakis, S
    Vafiadis, I
    Tzathas, C
    Avgerinos, A
    Sypsa, V
    Hatzakis, A
    HEPATOLOGY, 2000, 32 (04) : 354A - 354A
  • [37] Efficacy of daily interferon-alpha-2b (IFN-α) in combination with ribavirin in the treatment of non-responder patients with chronic hepatitis C (CHC):: A randomised-controlled trial.
    Tassopoulos, NC
    Tsantoulas, D
    Raptopoulou, M
    Paraskevas, E
    Vassiliadis, T
    Kanatakis, S
    Avgerinos, A
    Vafiadis, I
    Tzathas, C
    Ketikoglou, I
    Sypsa, V
    HEPATOLOGY, 2001, 34 (04) : 585A - 585A
  • [38] A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix BA®, among vaccine na⟨ve and vaccine non-responder dialysis patients
    Elhanan, E.
    Boaz, M.
    Schwartz, I.
    Schwartz, D.
    Chernin, G.
    Soetendorp, H.
    Oz, A. Gal
    Agbaria, A.
    Weinstein, T.
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2018, 22 (01) : 151 - 158
  • [39] Expression of IFNλ4 in liver and PBMC is closely associated with higher basal expression of ISGs and impaired induction of IL28B by interferon treatment in chronic hepatitis C non-responder patients
    Murakawa, Miyako
    Asahina, Yasuhiro
    Nakagawa, Mina
    Sakamoto, Naoya
    Nitta, Sayuri
    Kawai-Kitahata, Fukiko
    Taniguchi, Miki
    Watanabe, Takako
    Itsui, Yasuhiro
    Kakinuma, Sei
    Watanabe, Mamoru
    HEPATOLOGY, 2014, 60 : 1065A - 1065A
  • [40] Ribavirin and interferon∝-2b combination therapy for 48 weeks in patients with chronic hepatitis C who either failed (non-responder) or relapsed (relapsers) from previous interferon monotherapy.
    Tsai, NC
    Coste, A
    Shimoda, N
    Yee, H
    Jao, R
    Wong, L
    Buto, S
    Shimoda, S
    HEPATOLOGY, 1999, 30 (04) : 268A - 268A
12345